These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 19608558)

  • 1. Cost-effectiveness analysis of influenza and pneumococcal vaccination for Hong Kong elderly in long-term care facilities.
    You JH; Wong WC; Ip M; Lee NL; Ho SC
    J Epidemiol Community Health; 2009 Nov; 63(11):906-11. PubMed ID: 19608558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of influenza and pneumococcal vaccinations among elderly people in Japan.
    Cai L; Uchiyama H; Yanagisawa S; Kamae I
    Kobe J Med Sci; 2006; 52(3-4):97-109. PubMed ID: 16855372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales.
    Melegaro A; Edmunds WJ
    Vaccine; 2004 Oct; 22(31-32):4203-14. PubMed ID: 15474710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccination versus treatment of influenza in working adults: a cost-effectiveness analysis.
    Rothberg MB; Rose DN
    Am J Med; 2005 Jan; 118(1):68-77. PubMed ID: 15639212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines.
    Rozenbaum MH; Sanders EA; van Hoek AJ; Jansen AG; van der Ende A; van den Dobbelsteen G; Rodenburg GD; Hak E; Postma MJ
    BMJ; 2010 Jun; 340():c2509. PubMed ID: 20519267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors predictive of increased influenza and pneumococcal vaccination coverage in long-term care facilities: the CMS-CDC standing orders program Project.
    Bardenheier BH; Shefer A; McKibben L; Roberts H; Rhew D; Bratzler D
    J Am Med Dir Assoc; 2005; 6(5):291-9. PubMed ID: 16165069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cost effectiveness of influenza vaccination for adults aged 50 to 64 years: a model-based analysis for Spain.
    Aballéa S; De Juanes JR; Barbieri M; Martin M; Chancellor J; Oyagüez I; Verwee B; Largeron N
    Vaccine; 2007 Sep; 25(39-40):6900-10. PubMed ID: 17764790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pharmaco-economic aspects of vaccination against invasive pneumococcal infections in persons over 65 years of age; review of the literature on cost effectiveness analysis].
    Postma MJ; Heijnen ML; Beutels P; Jager JC
    Ned Tijdschr Geneeskd; 2002 May; 146(18):855-9. PubMed ID: 12038224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of the introduction of the pneumococcal polysaccharide vaccine in elderly Colombian population.
    Castañeda-Orjuela C; Alvis-Guzmán N; Paternina AJ; De la Hoz-Restrepo F
    Vaccine; 2011 Oct; 29(44):7644-50. PubMed ID: 21854825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Splenectomy and pneumococcal vaccination].
    Postma MJ; Heijnen MA; de Vries R; Beutels P; Jager JC
    Ned Tijdschr Geneeskd; 2003 Jun; 147(23):1141-2; author reply 1142. PubMed ID: 12822527
    [No Abstract]   [Full Text] [Related]  

  • 11. Cost-effectiveness of influenza vaccination in working-age cancer patients.
    Avritscher EB; Cooksley CD; Geraci JM; Bekele BN; Cantor SB; Rolston KV; Elting LS
    Cancer; 2007 Jun; 109(11):2357-64. PubMed ID: 17457827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines.
    Tyo KR; Rosen MM; Zeng W; Yap M; Pwee KH; Ang LW; Shepard DS
    Vaccine; 2011 Sep; 29(38):6686-94. PubMed ID: 21745516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-Effectiveness of the 4 Pillars Practice Transformation Program to Improve Vaccination of Adults Aged 65 and Older.
    Smith KJ; Zimmerman RK; Nowalk MP; Lin CJ
    J Am Geriatr Soc; 2017 Apr; 65(4):763-768. PubMed ID: 28024090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of a recommendation of universal mass vaccination for seasonal influenza in the United States.
    Clements KM; Chancellor J; Nichol K; DeLong K; Thompson D
    Value Health; 2011; 14(6):800-11. PubMed ID: 21914499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic evaluation of oseltamivir phosphate for postexposure prophylaxis of influenza in long-term care facilities.
    Risebrough NA; Bowles SK; Simor AE; McGeer A; Oh PI
    J Am Geriatr Soc; 2005 Mar; 53(3):444-51. PubMed ID: 15743287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Economic evaluation of an infant immunization program in Mexico, based on 13-valent pneumococcal conjugated vaccines].
    Muciño-Ortega E; Mould-Quevedo JF; Farkouh R; Strutton D
    Value Health; 2011; 14(5 Suppl 1):S65-70. PubMed ID: 21839902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis of vaccinations and decision makings on vaccination programmes in Hong Kong: A systematic review.
    Wong CKH; Liao Q; Guo VYW; Xin Y; Lam CLK
    Vaccine; 2017 May; 35(24):3153-3161. PubMed ID: 28476628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacoeconomics of elderly vaccination against invasive pneumococcal infections: cost-effectiveness analyses and implications for The Netherlands.
    Postma MJ; Heijnen ML; Beutels P; Jager JC
    Expert Rev Vaccines; 2003 Aug; 2(4):477-82. PubMed ID: 14711333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Vaccination of the elderly against pneumococcal disease is cost-efficient. Mass vaccination of all aged 65 and over is recommended].
    Ortqvist A; Jönsson B; Baltussen R; Ament A
    Lakartidningen; 2000 Nov; 97(45):5120-5. PubMed ID: 11116891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-benefit and cost-effectiveness of the incorporation of the pneumococcal 7-valent conjugated vaccine in the routine vaccination schedule of Catalonia (Spain).
    Navas E; Salleras L; Gisbert R; Domínguez A; Timoner E; Ibáñez D; Prat A
    Vaccine; 2005 Mar; 23(17-18):2342-8. PubMed ID: 15755625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.